Solid Lipid Nanoparticles

  • Anne Saupe
  • Thomas Rades

Keywords

Surfactant Doxorubicin Cavitation Triglyceride Clozapine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barratt, G.M. Therapeutic applications of colloidal drug carriers. Pharmaceutical Science & Technology Today, 2000. 3(5): 163-171.CrossRefGoogle Scholar
  2. 2.
    Barratt, G. Colloidal drug carriers: achievements and perspectives. Cellular and Molecular Life Sciences (CMLS), 2003. 60(1): 21-37.CrossRefGoogle Scholar
  3. 3.
    Zweers, M.L., Engbers, G.H., Grijpma, D.W. and Feijen, J. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide). Journal of Controlled Release, 2004. 100(3): 347-356.CrossRefPubMedGoogle Scholar
  4. 4.
    Muller, R.H., Maassen, S., Weyhers, H., Specht, F. and Lucks, J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. International Journal of Pharmaceutics, 1996. 138(1): 85-94.CrossRefGoogle Scholar
  5. 5.
    Schwarz, C., Mehnert, W., Lucks, J.S. and Muller, R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. Journal of Controlled Release, 1994. 30(1): 83-96.Google Scholar
  6. 6.
    Muller, R.H., Ruhl, D., Runge, S., SchulzeForster, K. and Mehnert, W. Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant. Pharmaceutical Research, 1997. 14(4): 458-462.CrossRefPubMedGoogle Scholar
  7. 7.
    Heydenreich, A.V., Westmeier, R., Pedersen, N., Poulsen, H.S. and Kristensen, H.G. Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity. International Journal of Pharmaceutics, 2003. 254(1): 83-87.CrossRefPubMedGoogle Scholar
  8. 8.
    Gohla, S.H. and Dingler, A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Die Pharmazie, 2001. 56(1): 61-63.PubMedGoogle Scholar
  9. 9.
    Ugazio, E., Cavalli, R. and Gasco, M.R. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). International Journal of Pharmaceutics, 2002. 241(2): 341-344.CrossRefPubMedGoogle Scholar
  10. 10.
    Trotta, M., Debernardi, F. and Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. International Journal of Pharmaceutics, 2003. 257 (1-2): 153-160.CrossRefPubMedGoogle Scholar
  11. 11.
    Venkateswarlu, V. and Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. Journal of Controlled Release, 2004. 95 (3): 627-638.CrossRefPubMedGoogle Scholar
  12. 12.
    Lim, S.J. and Kim, C.K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. International Journal of Pharmaceutics, 2002. 243(1-2): 135-146.CrossRefPubMedGoogle Scholar
  13. 13.
    Mehnert, W. and Mader, K. Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 2001. 47(2-3): 165-196.CrossRefPubMedGoogle Scholar
  14. 14.
    Bunjes, H., Westesen, K. and Koch, M.H.J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. International Journal of Pharmaceutics, 1996. 129 (1-2): 159-173.CrossRefGoogle Scholar
  15. 15.
    Muehlen, A.Z., Muehlen, E.Z., Niehus, H. and Mehnert, W. Atomic Force Microscopy Studies of Solid Lipid Nanoparticles. Pharmaceutical Research, 1996. 13(9): 1411-1416.CrossRefGoogle Scholar
  16. 16.
    Westesen, K., Bunjes, H. and Koch, M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release, 1997. 48(2-3): 223-236.CrossRefGoogle Scholar
  17. 17.
    Cavalli, R., Caputo, O., Carlotti, M.E., Trotta, M., Scarnecchia, C. and Gasco, M.R. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. International Journal of Pharmaceutics, 1997. 148(1): 47-54.CrossRefGoogle Scholar
  18. 18.
    Lippacher, A., Muller, R.H. and Mader, K. Semisolid SLN(TM) dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. European Journal of Pharmaceutics and Biopharmaceutics,2002. 53(2): 155-160.CrossRefPubMedGoogle Scholar
  19. 19.
    Wissing, S.A. and Muller, R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. European Journal of Pharmaceutics and Biopharmaceutics, 2003. 56(1): 67-72.CrossRefPubMedGoogle Scholar
  20. 20.
    Wissing, S.A. and Muller, R.H. Cosmetic applications for solid lipid nanoparticles (SLN). International Journal of Pharmaceutics, 2003. 254(1): 65-68.CrossRefPubMedGoogle Scholar
  21. 21.
    Jenning, V., Gysler, A., Schafer-Korting, M. and Gohla, S.H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. European Journal of Pharmaceutics and Biopharmaceutics, 2000. 49(3): 211-218.CrossRefPubMedGoogle Scholar
  22. 22.
    Saupe, A., Pharmaceutical and cosmetic applications of nanostructured lipid carriers (NLC): sun protection and care. 2004, Free University of Berlin.Google Scholar
  23. 23.
    Pouton, C.W., Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. European Journal of Pharmaceutical Sciences, 2000. 11(Supplement 2): S93-S98.CrossRefPubMedGoogle Scholar
  24. 24.
    Yang, S., Zhu, J., Lu, Y., Liang, B. and Yang, C. Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration. Pharmaceutical Research, 1999. 16 (5): 751-757.CrossRefPubMedGoogle Scholar
  25. 25.
    Mei, Z., Li, X., Wu, Q., Hu, S. and Yang, X. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacological Research, 2005. 51(4): 345-351.CrossRefPubMedGoogle Scholar
  26. 26.
    Zara, G.P., Cavalli, R., Fundaro, A., Bargoni, A., Caputo, O. and Gasco, M.R. Pharmacokinetics of Doxorubicin incorporated in solid lipid nanosheres (SLN). Pharmacological Research, 1999. 40(3): 281-286.CrossRefPubMedGoogle Scholar
  27. 27.
    Olbrich, C., Mueller, R.H., Tabatt, K., Kayser, O., Schulze, C. and Schade, R. Stable biocompatible adjuvants--a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern. Lab. Anim., 2002. 30 (4): 443-58.PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • Anne Saupe
    • 1
  • Thomas Rades
    • 2
  1. 1.School of PharmacyUniversity of OtagoDunedinNew Zealand
  2. 2.School of PharmacyUniversity of OtagoDunedinNew Zealand

Personalised recommendations